Stock ALRN AILERON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
3.23 USD +1.57% Intraday chart for Aileron Therapeutics, Inc. +3.19% +5.95%
May. 16 Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes CI
May. 16 Aileron Therapeutics, Inc. Announces Executive Changes CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aileron Therapeutics Closes Direct Offering of Shares, Warrants
MT
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Aileron Therapeutics Acquires Lung Therapeutics in Stock-for-Stock Deal
MT
Aileron Therapeutics, Inc. acquired Lung Therapeutics, Inc.
CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Aileron Therapeutics Announces Exploration of Strategic Alternatives
CI
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
CI
Aileron Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price Requirement
MT
Aileron Therapeutics Launches One-for-20 Reverse Stock Split
MT
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Aileron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
CI
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALRN Stock
  4. News Aileron Therapeutics, Inc.
  5. Highlights